CORDIS
Forschungsergebnisse der EU

CORDIS

Deutsch DE

Immunostimulatory Agonist antibodies for Cancer Therapy

Projektinformationen

ID Finanzhilfevereinbarung: 602262

Status

Abgeschlossenes Projekt

  • Startdatum

    1 November 2013

  • Enddatum

    31 Oktober 2017

Finanziert unter:

FP7-HEALTH

  • Gesamtbudget:

    € 8 227 907,60

  • EU-Beitrag

    € 5 995 747

Koordiniert durch:

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Deutschland

Ziel

"This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immunotherapeutics constitute a clinically effective, marketable drug concept. Ipilimumab is an antagonist immunostimulatory antibody (IS-Ab) that removes the restraint on the immune response by blocking inhibitory receptors on immune cells. Potent immunity can also be elicited by means of agonist IS-Abs that engage activatory receptors. Our program will translate the agonist IS-Ab concept into clinical treatments. This is critical, because a repertoire of complementary drugs that act at different points in the immune regulatory network will be required to counter immune failure in different cancer (sub-)types.
Our initiative is supported by longstanding experience as well as by the availability of clinical lead Abs. Pivotal are two clinical trials in which cancer type and treatment regimen have been selected to approximate pre-clinical settings in which striking therapeutic impact with agonist IS-Abs has been obtained. These studies will involve extensive analysis of efficacy-related biomarkers by means of validated assays, not only in blood samples, but also in the most relevant compartment: the tumor microenvironment. While our state-of-the-art agonist IS-Abs are being tested in the clinic, a parallel SME-driven effort will aim at the development of 2nd generation agonist IS-Abs with superior therapeutic index. This innovation is supported by proprietary technology and will result in intellectual property and marketable drugs. Taken together, our interdisciplinary platform is designed to yield maximal benefit for health care, academia and health-related industries in Europe."
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Koordinator

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Adresse

Im Neuenheimer Feld 280
69120 Heidelberg

Deutschland

Aktivitätstyp

Research Organisations

EU-Beitrag

€ 363 973

Kontakt Verwaltung

Rienk Offringa (Prof.)

Beteiligte (9)

UNIVERSITATSKLINIKUM HEIDELBERG

Deutschland

EU-Beitrag

€ 981 860

UNIVERSITY OF SOUTHAMPTON

Vereinigtes Königreich

EU-Beitrag

€ 1 295 820

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA

Spanien

EU-Beitrag

€ 306 304

UNIVERSIDAD DE NAVARRA

Spanien

EU-Beitrag

€ 299 600

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Italien

EU-Beitrag

€ 306 500

GLYCOTOPE GMBH

Deutschland

EU-Beitrag

€ 448 426

BIOINVENT INTERNATIONAL AB

Schweden

EU-Beitrag

€ 448 399

LEADARTIS S.L.

Spanien

EU-Beitrag

€ 448 465

BIONTECH RNA PHARMACEUTICALS GMBH

Deutschland

EU-Beitrag

€ 1 096 400

Projektinformationen

ID Finanzhilfevereinbarung: 602262

Status

Abgeschlossenes Projekt

  • Startdatum

    1 November 2013

  • Enddatum

    31 Oktober 2017

Finanziert unter:

FP7-HEALTH

  • Gesamtbudget:

    € 8 227 907,60

  • EU-Beitrag

    € 5 995 747

Koordiniert durch:

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Deutschland